Warm autoimmune hemolytic anemia is a rare and serious disorder with limited treatment options; RBC transfusions can provide short term relief but do not help correct the complicated pathogenesis. Autoantibodies coat RBCs marking them for macrophage phagocytosis shortening RBC lifespan and increasing RBC clearance. Several new drugs targeting the spleen tyrosine kinase, including sovleplenib, are under investigation since this kinase…